Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study
Paolo Cravedi(Icahn School of Medicine at Mount Sinai), Piero Ruggenenti(Mario Negri Institute for Pharmacological Research), Maria Chiara Sghirlanzoni(Azienda Ospedaliero-Universitaria delle Marche), Maddalena Marasà(Azienda Ospedaliero-Universitaria delle Marche), Giuseppe Remuzzi(Mario Negri Institute for Pharmacological Research), Alessandra Salerno(Azienda Ospedaliero-Universitaria delle Marche)
Cited by 71
Related Papers
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
|The Lancet|1999|909
Overview of Complement Activation and Regulation
|Seminars in Nephrology|2013|864